Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Neurotech International ( (AU:NTI) ).
Neurotech International has reported promising results from its pharmacokinetic study of NTI164, a CBDA-rich cannabinoid formulation, demonstrating its safety and efficacy for paediatric use. The study supports NTI164’s potential as a treatment for neurological disorders, with ongoing regulatory submissions in the US and Australia. Additionally, NTI164 has shown significant clinical improvements in Rett Syndrome, with results published in a scientific journal, highlighting its therapeutic potential and reinforcing its regulatory advancement prospects.
More about Neurotech International
Neurotech International Ltd is a clinical-stage biopharmaceutical company focused on developing treatments for paediatric neurological disorders. The company is advancing its proprietary cannabinoid formulation, NTI164, which targets conditions like autism spectrum disorder, Rett Syndrome, and PANDAS/PANS, with a focus on anti-inflammatory and neuroprotective properties.
Average Trading Volume: 592,901
Technical Sentiment Signal: Sell
Current Market Cap: A$23.09M
See more insights into NTI stock on TipRanks’ Stock Analysis page.